Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Intra-Cellular Therapies Inc shares valued at $2,038,079 were sold by Halstead Michael on Nov 12 ’24. At $89.12 per share, Halstead Michael sold 22,869 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Halstead Michael sold 18,714 shares, netting a total of over 1,654,021 in proceeds. Following the sale of shares at $88.38 each, the insider now holds 0 shares.
Before that, Halstead Michael had added 41,583 shares to its account. In a trade valued at $3,704,223, the Officer bought Intra-Cellular Therapies Inc shares for $89.08 each.
As published in a research note from Piper Sandler on September 06, 2024, Intra-Cellular Therapies Inc [ITCI] has been rated up from a Neutral to an Overweight and the price target has been revised to $92 from $68. Analysts at Robert W. Baird started covering the stock with ‘”an Outperform”‘ outlook in a report released in early January. As of December 11, 2023, TD Cowen has initiated its “an Outperform” rating for ITCI. Earlier on April 20, 2023, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for ITCI stock.
Analyzing ITCI Stock Performance
During the last five days, there has been a surge of approximately 1.11%. Over the course of the year, Intra-Cellular Therapies Inc shares have jumped approximately 20.90%. Shares of the company reached a 52-week high of $93.45 on 11/11/24 and a 52-week low of $62.78 on 02/22/24. A 50-day SMA is recorded $79.91, while a 200-day SMA reached $73.56. Nevertheless, trading volume fell to 0.4 million shares from 0.46 million shares the previous day.
Support And Resistance Levels for Intra-Cellular Therapies Inc (ITCI)
According to the 24-hour chart, there is a support level at 85.55, which, if violated, would cause prices to drop to 84.52. In the upper region, resistance lies at 87.20. The next price resistance is at 87.82. RSI (Relative Strength Index) is 58.16 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.51, which suggests the price will decrease in the coming days. Percent R is at 59.04%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
